Eli Lilly & Co. (LLY) Misses Q2 EPS by 46c ; Offers Guidance

Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $8.38, $0.46 worse than the analyst estimate of $8.84. Revenue for the quarter came in at $22.97 billion versus the consensus estimate of $20.56 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2026 revenue of $85-87 billion, versus the consensus of $85.4 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• Intel said to give no shares to about 33% of orders in offering
• Mereo BioPharma (MREO) Reports In-Line Q2 EPS
• Capital One credit card shift to Discover seen limited